BTK
Los inhibidores de la tirosina quinasa de Bruton (BTK) son compuestos que específicamente se dirigen e inhiben la BTK, una enzima crucial involucrada en la señalización del receptor de células B y en la regulación de la angiogénesis. La BTK desempeña un papel significativo en la proliferación y supervivencia de las células cancerosas, particularmente en las malignidades hematológicas. Al inhibir la BTK, estos compuestos pueden interrumpir la angiogénesis y el crecimiento tumoral, lo que los convierte en valiosos en la terapia contra el cáncer. En CymitQuimica, ofrecemos una gama de inhibidores de BTK de alta calidad para apoyar su investigación en oncología, inmunología y angiogénesis.
Se han encontrado 146 productos de "BTK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
TLT8
<p>TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.</p>Forma y color:Odour SolidIbrutinib-biotin
CAS:<p>Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).</p>Fórmula:C56H80N12O9SPureza:98%Forma y color:SolidPeso molecular:1097.39FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Forma y color:LiquidBTK inhibitor 19
CAS:<p>BTK inhibitor 19 is a highly selective, covalent BTK inhibitor ( IC 50 = 2.7 nM).</p>Fórmula:C25H24F3N7O3Forma y color:SolidPeso molecular:527.508PROTAC BTK Degrader-12
CAS:<p>PROTAC BTK Degrader-12 (EXAMPLE 19) is a PROTAC-based BTK degrader, featuring a structure where the BTK ligand and linker are highlighted in pink and black, the linker in black, and the VHL ligand in blue.</p>Fórmula:C47H54N12O4Forma y color:SolidPeso molecular:851.01BTK-IN-5
CAS:<p>BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases,</p>Fórmula:C23H32N4O5Forma y color:SolidPeso molecular:444.532Tyrosinase-IN-16
CAS:<p>Tyrosinase-IN-16 inhibited tyrosinase.</p>Fórmula:C8H6BrN3SPureza:99.57%Forma y color:SolidPeso molecular:256.12PROTAC BTK Degrader-1
CAS:<p>Potent, selective oral PROTAC BTK Degrader-1; IC50: 34.51 nM (WT), 64.56 nM (BTK-481S); reduces BTK protein, inhibits tumors.</p>Fórmula:C43H43N9O4Forma y color:SolidPeso molecular:749.86BIIB091
CAS:<p>BIIB091 is a highly selective, reversible BTK inhibitor for treating autoimmune diseases.</p>Fórmula:C28H34N10O2Forma y color:SolidPeso molecular:542.648BCPyr
CAS:<p>BCPyr is a new candidate BTK degrader ( DC 50 = 800 nM).</p>Fórmula:C58H65F2N11O8Forma y color:SolidPeso molecular:1082.224FDU73
<p>FDU73 is a potent and selective BTK PROTAC degrader with a DC50 of 2.9 nM in JeKo-1 cells. It inhibits tumor cell proliferation and exhibits antitumor activity.</p>Forma y color:Odour SolidPROTAC BTK Degrader-9
<p>PROTACBTK Degrader-9 (compound 23) is a potent PROTACs degrader that specifically targets BTK. It effectively downregulates the RANKL-activated BTK-PLCγ2-Ca2+-NFATc1 signaling pathway. Consequently, PROTACBTK Degrader-9 inhibits osteoclastogenesis and reduces alveolar bone resorption in a mouse model of periodontitis.</p>Fórmula:C46H52FN13O5Peso molecular:885.41984CNX-500
CAS:<p>CNX-500: covalent Btk inhibitor linked to biotin, IC50 0.5 nM, low effect on EGFR and Src kinases.</p>Fórmula:C48H68N10O9SPureza:98%Forma y color:SolidPeso molecular:961.18PROTAC BTK Degrader-2
CAS:<p>PROTAC BTK Degrader-2, a potent degrader of BTK through the PROTAC mechanism, effectively diminishes BTK protein levels [1].</p>Fórmula:C47H54F2N8O13Forma y color:SolidPeso molecular:976.97PROTAC BTK Degrader-8
<p>PROTACBTK Degrader-8 (compound 3) is an efficient PROTAC BTK degrader with a linker that can couple with ADC antibodies to form PAC.</p>Fórmula:C80H94F2N14O20P2Peso molecular:1670.62121PTD10
CAS:<p>PTD10, a highly potent PROTAC BTK degrader, exhibits a DC50 of 0.5 nM and a KD of 2.28 nM.</p>Fórmula:C49H51N11O8Pureza:98%Forma y color:SolidPeso molecular:922BRK inhibitor P21d hydrochloride
CAS:<p>BRK inhibitor P21d HCl targets breast tumor kinase with 30 nM IC50, suppresses p-SAM68 at 52 nM, useful for in vivo breast cancer research.</p>Fórmula:C23H23ClFN7O2Forma y color:SolidPeso molecular:483.93BTK ligand-14
<p>BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.</p>Forma y color:Odour SolidAcalabrutinib enantiomer
CAS:<p>R-Acalabrutinib, a BTK inhibitor,enantiomer, is researched for cancer, autoimmune diseases, and inflammation.</p>Fórmula:C26H23N7O2Pureza:97.27%Forma y color:SolidPeso molecular:465.51DBt-10
<p>DBt-10 is a potent Bruton's tyrosine kinase (BTK) degrader [1].</p>Fórmula:C68H86ClFN16O6Pureza:98%Forma y color:SolidPeso molecular:1277.96
